Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma

PURPOSE: Standard frontline treatment of patients with metastatic renal cell carcinoma currently includes sunitinib. A barrier to long-term treatment with sunitinib includes the development of significant adverse effects, including diarrhea, hand-foot syndrome (HFS), and fatigue. This trial assessed...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: Jonasch, Eric, Slack, Rebecca S., Geynisman, Daniel M., Hasanov, Elshad, Milowsky, Matthew I., Rathmell, W. Kimryn, Stovall, Summer, Juarez, Donna, Gilchrist, Troy R., Pruitt, Lisa, Ornstein, Moshe C., Plimack, Elizabeth R., Tannir, Nizar M., Rini, Brian I.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6804828/
https://ncbi.nlm.nih.gov/pubmed/29641297
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.77.1485
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares